National Complex
Dedicated to the protection of Consumer Rights and Fair Competition National Complex litigation practice request your free consultation
Free Case Consultation

Consumer Protection

State and federal laws provide consumers with broad protection from false and misleading advertising and unfair or deceptive business acts or practices.

Gustafson Gluek PLLC has led class action lawsuits on behalf of consumers involving claims about falsely marketed life insurance, defective hardware in consumer computers, misleading air compressor labeling, and rental car overcharges.

  • Bhatia, D.D.S. et al. v. 3M Company – Gustafson Gluek serves as Co-Lead Counsel in a case on behalf of dentists who bought 3M Lava Ultimate Restorative material for use in dental crowns. The 3M Lava material failed at an unprecedented rate, leading to substantial loss of time and money for the dentists.
  • In re: FCA US LLC Monostable Electric Gearshift Litigation – Gustafson Gluek serves on the Plaintiffs’ Steering Committee representing consumers who bought cars with defective gearshifts that did not provide a reliable method of determining gear placement.
  • Budget Rent a Car – The firm represented a class in a case against Budget Rent a Car that settled on terms very favorable to the class. Plaintiffs alleged that Budget unfairly and without notice charged renters more money (in many instances hundreds of dollars more) for bringing their car back early. After Gustafson Gluek helped get a class certified and won a summary adjudication motion, Budget agreed to return 100% of the overcharges – in cash – to each renter and to clearly disclose its practices going forward.
  • Yarrington, et al. v. Solvay Pharmaceuticals, Inc. – Gustafson Gluek was one of two firms appointed Co-Lead Counsel by the U.S. District Court in Minnesota to represent those persons who purchased and ingested Estratest and Estratest H.S., hormone replacement therapy drugs, after March 8, 1998 in all states except California. Plaintiffs alleged that Defendant falsely and deceptively advertised the drugs as being “FDA-approved.” Following nearly six years of hard-fought litigation, Defendant agreed to pay $16.5 million, which allowed class members to recover 100% of their claimed damages.
request your free case consultation fill out the form below
  • This field is for validation purposes and should be left unchanged.
all fields required